Moreover, a phase II clinical trial with 20 patients with recurrent prostate cancer conducted by Alumkal et al. showed that the administration of 200 μmoles/day of sulforaphane-rich extract resulted in an approximate 50% reduction in PSA doubling time [12]. This evidence concerns the gene KLK3 and prostate cancer.